MapLight Therapeutics Initiated Buy by TD Cowen TD Cowen initiated coverage of MapLight Therapeutics on Apr 7, 2026 (Investing.com); Fazen models show a 22% base-case upside over 12 months under current assumptions.

MapLight Therapeutics Initiated Buy by TD Cowen: TD Cowen initiated coverage of MapLight Therapeutics on Apr 7, 2026 (Investing.com); Fazen models show a 22% base-case upside over 12 months under current… 👈 Read full analysis #MapLightTherapeutics #TDCowen #Investing #StockMarket #FinancialNews

MapLight shares track up after $251m IPO MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

#Neuropsychiatric disorder specialist #MapLightTherapeutics has made its debut on the #Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

Funding Raises: #xAI $5B Corporate Round; #Ramp $500M Series E-2; #MaplightTherapeutics $372.5M Series D; #AmbienceHealthcare $243M Series C; #Lovable $200M Series A; #Fractal $172M Secondary Market; #Observe $156M Series C; #Anaconda $150M Series C; #Motive $150M Series G